Mesa Laboratories | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 60.74 M

Revenue: As of FY2026 Q2, the actual value is USD 60.74 M, beating the estimate of USD 60.73 M.

EPS: As of FY2026 Q2, the actual value is USD 0.45, beating the estimate of USD 0.16.

EBIT: As of FY2026 Q2, the actual value is USD 7.586 M.

Sterilization and Disinfection Control

• Revenues: $22,107 for the three months ended September 30, 2025, a decrease of 0.4% compared to the prior year period.
• Gross Profit: $14,870, representing 67.3% of revenues, a decrease of 1.0 percentage point from the prior year period.

Biopharmaceutical Development

• Revenues: $13,920 for the three months ended September 30, 2025, an increase of 17.3% compared to the prior year period.
• Gross Profit: $8,129, representing 58.4% of revenues, a decrease of 2.0 percentage points from the prior year period.

Calibration Solutions

• Revenues: $13,570 for the three months ended September 30, 2025, an increase of 10.7% compared to the prior year period.
• Gross Profit: $8,235, representing 60.7% of revenues, an increase of 1.9 percentage points from the prior year period.

Clinical Genomics

• Revenues: $11,140 for the three months ended September 30, 2025, a decrease of 3.1% compared to the prior year period.
• Gross Profit: $6,097, representing 54.7% of revenues, an increase of 3.3 percentage points from the prior year period.

Cash Flow

• Net Cash Provided by Operating Activities: $10,115 for the six months ended September 30, 2025, a decrease from $16,014 in the prior year period.
• Net Cash Used in Investing Activities: -$2,101 for the six months ended September 30, 2025.
• Net Cash Used in Financing Activities: -$16,310 for the six months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to reinvest approximately $0.9 million of cost savings into the Sterilization and Disinfection Control division to accelerate growth, with expected net annualized cost reductions of approximately $2.3 million starting in the third quarter of fiscal year 2026.
• Non-Core Business: The company anticipates continued revenue growth outside of China for Clinical Genomics but expects continued decreases in revenues from China due to ongoing macroeconomic and regulatory uncertainty.